Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older, of any gender
- People who have been diagnosed with a specific type of aggressive blood cancer called diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma, where the cancer has come back after treatment or did not respond to treatment, and who have already received at least one round of treatment
- People whose cancer can be measured on scans, according to standard lymphoma measurement guidelines
- People with normal liver function, moderate liver problems, or severe liver problems — the trial has separate groups (Arms A, B, and C) for each level, with specific blood test results required for each group (confirm exact values with trial site)
- People with a general health and activity level that falls within an acceptable range, as measured by a standard medical scale (ECOG 0–2 for normal liver function; ECOG 0–3 for those with liver problems)
- People whose kidneys, blood, and other organs are functioning adequately
- Women who could become pregnant must agree to use highly effective contraception from the time of consent until at least 10 months after the last dose; men with female partners who could become pregnant must agree to use a condom or abstain from sex from the first dose until at least 7 months after the last dose
Who may not be able to join:
- People who have previously been treated with the study drug, loncastuximab tesirine
- People who have had a stem cell transplant (using their own or a donor's cells) within the 60 days before starting the study
- People who are HIV positive
- People with a chronic hepatitis B virus (HBV) infection who are unwilling or unable to take standard antiviral preventive medication, or who have a detectable level of the virus in their blood
- People with a hepatitis C virus (HCV) infection who have not completed curative treatment, or who still have a detectable level of the virus in their blood
- People with a history of severe skin reactions known as Stevens-Johnson syndrome or toxic epidermal necrolysis
- People whose lymphoma has spread to the brain or spinal fluid at the time of screening
- People who are pregnant or currently breastfeeding
- People with serious other medical conditions that may affect participation (confirm specific conditions with trial site)
- People who have had major surgery, radiation, chemotherapy, or other cancer treatments within 14 days before starting the study (exceptions may apply if approved by the trial sponsor)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 954-903-7994
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants with Moderate or Severe Hepatic Impairment Who Experience a Dose-Limiting Toxicity (DLT)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.